Reaction of Neuronal Nitric-oxide Synthase with Oxygen at Low Temperature
EVIDENCE FOR REDUCTIVE ACTIVATION OF THE OXY-FERROUS COMPLEX BY TETRAHYDROBIOPTERIN*

Nicole BecDagger , Antonius C. F. Gorren§, Christof Voelker§, Bernd Mayer§, and Reinhard LangeDagger

From the Dagger  Institut National de la Santé et de la Recherche Scientifique, U 128, Institut Fédératif de Recherche 24, 34293 Montpellier, France and the § Institut für Pharmakologie und Toxikologie, Karl-Franzens-Universität, 8010 Graz, Austria

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The reaction of reduced NO synthase (NOS) with molecular oxygen was studied at -30 °C. In the absence of substrate, the complex formed between ferrous NOS and O2 was sufficiently long lived for a precise spectroscopic characterization. This complex displayed similar spectral characteristics as the oxyferrous complex of cytochrome P450 (lambda max = 416.5 nm). It then decomposed to the ferric state. The oxidation of the flavin components was much slower and could be observed only at temperatures higher than -20 °C. In the presence of substrate (L-arginine), another, 12-nm blue-shifted, intermediate spectrum was formed. The breakdown of the latter species resulted in the production of Nomega -hydroxy-L-arginine in a stoichiometry of maximally 52% per NOS heme. This product formation took place also in the absence of the reductase domain of NOS. Both formation of the blue-shifted intermediate and of Nomega -hydroxy-L-arginine required the presence of tetrahydrobiopterin (BH4). We propose that the blue-shifted intermediate is the result of reductive activation of the oxygenated complex, and the electron is provided by BH4. These observations suggest that the reduction of the oxyferroheme complex may be the main function of BH4 in NOS catalysis.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Nitric-oxide synthase (EC 1.14.13.39; NOS)1 catalyzes the oxidation of L-arginine to L-citrulline and nitric oxide (NO) in two reaction cycles. The first one leads to the formation of Nomega -hydroxy-L-arginine (NOHLA), and the second one leads to the formation of L-citrulline and NO (1, 2). The latter reaction is not specific for NOS; the formation of L-citrulline and nitrite, an oxidation product of NO, has also been reported for cytochrome P450 (3). Similarly to cytochrome P450, NOS contains a thiolate ligated heme, NADPH is the initial electron donor, and the reaction requires molecular oxygen (O2), which has to be activated and split for the oxidation of L-arginine and the formation of water (4, 5). In contrast to P450, in NOS the entire electron transfer chain is contained in a single molecule, consisting of a flavin-containing reductase domain and a heme-containing oxygenase domain (6). Furthermore, it requires a cofactor, (6R)-5,6,7,8-Tetrahydro-L-biopterin (tetrahydrobiopterin; BH4), the role of which is still unclear but the presence of which is essential for NO synthesis (7, 8). In addition, Ca2+/calmodulin is required for electron flow from the reductase domain to the oxygenase domain (9).

NOS catalysis involves the interaction of the reduced enzyme with molecular oxygen. Although little is known about this process for NOS, a wealth of data is available about the analogous P450 system (10). As shown in Scheme 1, reduced P450 is known to react rapidly with oxygen to form a transient oxygen complex, which has been stabilized at low temperature (11). Several biophysical studies have elucidated the electronic structure of this complex as a Fe(II)O2 left-right-arrow  Fe(III)O2· equilibrium, which is poised in favor of the ferric form (Scheme 1, 1) (12-14). The subsequent reduction of this complex is thought to lead first to a peroxy compound (2) and eventually, after two protonation steps, to an iron(IV) porphyrin pi -cation radical (3). Both species 2 and 3 have been proposed to act as oxygenating agents (15). The breakdown of these species results in product release and formation of ferriheme via still unknown intermediates (4).


View larger version (3K):
[in this window]
[in a new window]
 
Scheme 1.   Supposed reaction of cytochrome P450 with oxygen within its catalytic cycle. The numbers refer to species cited in the text. For simplicity the possible interaction of 2 with substrate R-H is not shown.

The corresponding reactions for NOS have not been reported, except for a very recent stopped-flow study, which demonstrated the transient formation in the oxidation of ferrous NOS by O2 of a compound absorbing at 427 nm (16). In this work, we used a different approach to study the reaction between molecular oxygen and reduced neuronal NOS (nNOS). In order to trap possible intermediates, most of the experiments were carried out at subzero temperatures in the presence of 50% ethylene glycol as anti-freeze solvent (17). The same procedure was employed previously for the study of P450 oxygen complexes (11, 18, 19). Special attention was paid to the role of BH4 in the reduction of the oxygen complex in the presence of L-arginine. Our results throw more light on the function of BH4 in NOS catalysis.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Enzymes used for molecular biological procedures were from New England Biolabs (supplied by Biotrade, Vienna). The TA cloning kit from Invitrogen was from the same vendor. The Sequenase kit was obtained from Amersham Pharmacia Biotech (supplied by MedPro, Vienna). Oligonucleotides were synthesized by the Institute of Microbiology and Genetics at the Biocenter of the University of Vienna. Glutathione-agarose beads, thrombin, and all other chemicals were from Sigma. BH4 was from Alexis Biochemicals (Switzerland); 7,8-dihydro-L-biopterin (BH2) was from Schircks Laboratories (Switzerland); calmodulin, L-arginine, and NOHLA were from Sigma; L-[2,3,4,5-3H]arginine hydrochloride (57 Ci/mmol) was from Amersham Pharmacia Biotech and purified by HPLC before use. All other reagents were purchased from Merck except for CHAPS, which was from Boehringer Mannheim. Oxygen (99.995% pure) was from Aga (Toulouse, France).

Preparation of Nitric-oxide Synthase-- Recombinant rat brain nNOS was purified from baculovirus-infected insect cells as described previously (20). The holoenzyme contained tightly bound BH4 in the ratio of 0.5 per heme. BH4-free nNOS was obtained from Sf9 cells treated with 2,4-diamino-6-hydroxypyrimidine according to a published procedure (8). The nNOS oxygenase domain was cloned and expressed in Escherichia coli by a procedure to be published elsewhere. The molar concentrations of nNOS and its oxygenase domain were determined from absorption coefficients of the oxidized and the ferrous-CO complex according to Sono et al. (21).

Preparation of Cytochrome P450-- Cytochrome P450 CYP2B4 from rabbits, which had been under phenobarbital treatment for 1 week, was prepared according to the procedure of Coon et al. (22). The protein was kept frozen as a 69 µM solution in 10 mM potassium phosphate buffer, pH 6.8, containing 20% glycerol and 1 mM EDTA. The purified enzyme was electrophoretically homogenous, and in the oxidized state it displayed an absorbance ratio of R417/277 = 1.06. Neither NOS nor cytochrome P450 showed P420 characteristics.

Low Temperature Spectroscopy-- Base line-corrected absorbance spectra in the 350-700-nm range were recorded with a Cary 3E (Varian) spectrophotometer in the double beam mode, using a 1.5-nm slit width. Data acquisition was in steps of 0.5 nm, with an acquisition time of 0.033-0.5 s/data point. The instrument was equipped with a home-built double sample compartment, which allowed spectral recordings at low temperatures (down to -50 °C). Sample and reference cuvettes were placed in a bloc made of aluminum, which was thermostatted by circulation of ethanol, thermoregulated in a Haake F3-Q bath. Inside the cells, the temperature was monitored continuously with a thermocouple connected to an AOIP voltmeter. For thermal insulation, the sample compartment was surrounded by polyvinyl chloride walls, equipped with double quartz windows. Formation of ice and condensation of water on the windows was prevented by a flow of dry nitrogen.

Formation of Intermediate Oxygen Complexes-- To prevent freezing of the sample, the experiments were done in mixed organic solvents. If not specified otherwise, we used ethylene glycol/water (1:1, v/v). This solvent did not change significantly the spectral properties of NOS, it did not induce a transition to the P420 state, and in its presence the enzyme was still active in a standard assay (23). The buffer was 50 mM potassium phosphate, pH 7.2, containing 1 mM CHAPS, 0.5 mM EDTA, and 1 mM 2-mercaptoethanol. It contained no calmodulin, and, unless specified, no BH4 was added. For CYP2B4, the solvent was 50% glycerol, and the buffer was sodium phosphate, 50 mM, pH 7.4. The pH of these mixed solvents is known to vary only little as a function of temperature (17). The sodium dithionite stock solution (23 mM) was prepared in the same solvent. Prior to use, argon was bubbled through the solutions for 30 min. The enzymes were diluted in the oxygen-free buffers at final concentrations of 3 µM in Teflon closed cuvettes in total volumes of 2 ml. They were reduced at 15 °C by the addition of 20 µl of a concentrated solution of sodium dithionite (final concentration, 230 µM) using a Hamilton syringe. When reduction was complete, the temperature was decreased to the desired value (typically -30 °C). 2-5 ml of precooled oxygen were then bubbled in the enzyme solution with a syringe. This procedure took about 5 s, and thereafter the spectra were recorded in intervals of 2 min.

Product Analysis-- Reduction and oxygenation of NOS and its heme domain were carried out as described above, except for the presence of 500,000 cpm of 200 µM L-[2,3,4,5-3H]arginine. After incubation for 5-60 min at the specified temperature, the reaction was stopped by the addition of 75 µl HCl (1 M) to the reaction mixture (1 ml). After centrifugation with a bench-top centrifuge, 100 µl of the supernatant were injected into a 25-cm Nucleosil SA 100-5 HPLC column from Macherey & Nagel. The arginine derivatives were separated at room temperature in 50 mM sodium acetate, pH 6.5, at a flow rate of 1.5 ml/min. Fractions of 750 µl were collected for 30 min, and radioactivity was determined in each fraction by liquid scintillation counting. NOHLA was identified by comparison with an authentic standard (24). Its formation was quantified from its integrated elution peak relative to the total radioactivity. In one control experiment, we used NADPH and not dithionite to reduce nNOS. In that case, the phosphate buffer was replaced by triethanolamine, 50 mM, pH 7.4, and a procedure similar to that described by Abu-Soud et al. (25) was used. First, the heme iron of nNOS was reduced by 200 µM NADPH in the presence of 14 µM calmodulin and 1 mM calcium chloride in aqueous buffer at 15 °C under the experimental conditions we had employed for reduction by dithionite. After dissociation of calmodulin by excess EDTA (1.8 mM final concentration), 200 µM radiolabeled L-arginine, was added, and oxygen was bubbled through the solution. The production of NOHLA was then quantified as described above.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Oxygen Binding to Reduced nNOS in the Absence of Substrate-- Under anaerobic conditions, 230 µM dithionite reduced the NOS sample within 10-15 min at 15 °C. Spectrally, the reduction was characterized by a loss of the flavin absorbance, a shift of the Soret band from 400 to 410 nm, a shoulder at 455 nm, and a maximum at 554 nm. During the subsequent temperature decrease to -30 °C, the spectrum of Fe(II) nNOS remained essentially the same, except for a slight sharpening of the Soret band. After the addition of oxygen at -30 °C, the spectrum changed within 1 min. As shown in Fig. 1, the amplitude of the Soret band was slightly decreased, and its maximum was red-shifted to 416.5 nm. In the visible region, the main effect was a broadening of the absorption band. As shown in Fig. 2A, the oxygenated minus reduced difference spectrum showed a strong maximum at 426 nm, two sharp minima at 401 and 458 nm, and an isosbestic point at 415 nm. Furthermore, two broad maxima appeared around 500 and 600 nm, as well as a minimum at about 550 nm.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Spectral changes of reduced NOS (Fe2+) after the addition of oxygen at -30 °C. Reduced full-length nNOS (3 µM) was cooled to -30 °C, and then precooled oxygen was bubbled through the solution. The buffer, 50 mM potassium phosphate, pH 7.2, contained 1 mM CHAPS, 0.5 mM EDTA, 1 mM 2-mercaptoethanol, and 50% ethylene glycol. Spectra immediately after oxygen addition (Fe2+ + O2) and 45 min later (reoxidized) are shown.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Comparison with the oxyferrous complex of cytochrome P450. The P450 LM2 (···) difference spectra were normalized with respect to those of nNOS (------). A, formation of the oxygen complex; difference spectra between the oxygen complex minus the reduced state. The experimental conditions of nNOS were those of Fig. 1. For P450, 2 µM, the buffer was sodium phosphate, 50 mM, pH 7.4, containing 50% glycerol. B, decomposition of the oxygen complex; difference spectra in the course of reoxidation relative to the oxygen complex, 17 min (NOS) and 25 min (P450) after addition of oxygen.

At -30 °C, the slow decomposition of the oxygen complex led to an oxidized heme with reduced flavins (Fig. 1). As shown in Fig. 2A, the oxidized minus oxygen complex difference spectrum grew with maxima at 387.5, 418.5, 516.5, and 650 nm, minima at 442.5 and 558 nm, and an isosbestic point at 427 nm. The observed changes and the resulting spectrum are indicative of a mixture of high and low spin ferriheme but with a much higher fraction in the low spin state than before the experiment at 15 °C. Finally, when the temperature was raised above -20 °C, the flavins became also oxidized, as evidenced by a broad absorbance increase between 350 and 420, and between 470 and 550 nm (not shown). The latter reaction is probably due to a direct (nonphysiological) reaction of the reduced flavins with oxygen or with hydrogen peroxide resulting from the reaction of oxygen with dithionite.

As shown in Fig. 2, the spectral characteristics of formation and decomposition of the oxygen complex were similar to those observed with cytochrome P450. An exception was the trough at 458 nm in the difference spectrum (intermediate - reduced state, Fig. 2A), which was absent in P450. However, a comparison of the spectra of the reduced states shows that this spectral trough originates from the properties of the reduced state of NOS rather than from its oxygen complex. Indeed, the spectrum of reduced NOS, but not reduced P450, exhibits a shoulder at this wavelength. The differences observed during the autoxidation of the oxygen complex as compared with the analogous reaction in P450 (Fig. 2B), i.e. additional absorbance increases at 387.5, 516.5, and 650 nm, can be ascribed to the formation of a significant fraction high spin ferriheme.

The kinetics of oxygen binding and autoxidation were followed at 442.5 nm. Oxygen binding to reduced NOS was very rapid even at -30 °C. Subsequent oxidation of the heme was monoexponential (tau  = 6.5 min at -30 °C). Oxidation of the flavins could only be observed at considerably higher temperatures (tau  = 15.6 min at -11 °C).

Oxygen Binding in the Presence of Substrate-- The addition of L-arginine (200 µM) resulted in the well known shift of the heme iron spin equilibrium toward more high spin. This effect persisted in the presence of ethylene glycol and at low temperatures. Reduction gave rise to a spectrum very similar to that of substrate-free reduced nNOS (Fig. 3A). In this case, too, mixing of reduced nNOS with oxygen at -30 °C produced a detectable intermediate, but its Soret band was blue-shifted (lambda max = 404.5 nm) (Fig. 3B). In the visible region, the intermediate spectrum was similar to that obtained in the absence of L-arginine. At -30 °C, its decay kinetics resulted within 37 min in an oxidized type high spin enzyme. The difference spectra reflecting formation (intermediate - reduced state, Fig. 3C) and decomposition (reoxidized - intermediate) were strikingly different from those obtained in the absence of L-arginine (see above). The formation was characterized by a strong maximum at 375 nm and a double minimum at 417 and 453 nm. During the decomposition of the intermediate, a broad maximum appeared at 370 nm, with a shoulder at 420 nm and a minimum at 444 nm.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   The oxygen complex in the presence of L-arginine. A, reduced states of nNOS and P450 LM2 at -30 °C. nNOS in the absence (------) and in the presence (- - -) of 200 µM L-arginine, P450 LM2 (···). B, spectral evolution of nNOS in the presence of L-arginine after the addition of oxygen at -30 °C: reduced state (Fe2+), immediately after oxygen addition (intermediate), and 37 min later (reoxidized). C, difference spectra of NOS reflecting formation (intermediate - Fe2+) and reoxidation (reoxidized - intermediate) of the intermediate. The experimental conditions were those of Fig. 1.

BH4-free NOS-- In the absence of L-arginine, binding of oxygen to BH4-free NOS at -30 °C resulted in similar spectral changes as those observed with BH4-bound NOS (cf. "Discussion" and Table II); the autoxidation of the oxygen complex (lambda max = 415 nm), resulted in low spin ferric heme. In contrast, the presence of L-arginine did not induce the blue-shifted oxygen complex observed in BH4-bound NOS, and the spectral characteristics of the oxygen complex were close to those observed in the BH4-free NOS in the absence of L-arginine. As for the BH4-bound NOS in the presence of L-arginine, the autoxidation of this complex resulted in high spin ferric heme.

The Oxygenase Domain-- The spectral changes upon oxygen addition to the reduced oxygenase domain were recorded at -30 °C as described above, in the absence and presence of BH4 (20 µM) and L-arginine (200 µM). In all cases, a direct transition from the reduced to the oxidized state was observed, and no intermediate state could be detected. Whereas the cofactors did not significantly affect the spectrum of the reduced state, the final oxidized state was primarily low spin in the absence of substrate and high spin in the presence of L-arginine and/or BH4. As an example, the spectral changes in the presence of BH4 and L-arginine are shown in Fig. 4. Clear isosbestic points were observed at 406, 483, 534, and 595 nm. At -30 °C, the oxidation kinetics were relatively slow (tau  = 12.4 min) without being affected noticeably by L-arginine and/or BH4.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 4.   Time-dependent spectral evolution of reduced nNOS oxygenase domain, 4.5 µM, after the addition of oxygen at -30 °C in the presence of 200 µM L-arginine and 20 µM BH4. Other experimental conditions were those of Fig. 1. The reaction times are indicated in the figure. The blue shift of the Soret band is indicated by an arrow.

Oxygen Complex Decomposition Products-- One explanation for the blue-shifted oxygen complex of BH4-bound full-length NOS in the presence of L-arginine might be that it represents a later intermediate in the activation of oxygen, one electron reduced beyond the ferrous oxygenated species. Since such a state could in principal furnish the two electrons required for the oxidation of L-arginine to NOHLA and the concomitant reduction of oxygen to water, we decided to analyze the decomposition products of the reaction with radiolabeled L-arginine. Fig. 5 shows a typical HPLC profile of the reaction products. Only one radioactive reaction product was formed, and this had the same retention time as authentic NOHLA. Control experiments in the absence of enzyme with or without added BH4 showed no product formation, and no NOHLA was detected unless the enzyme was reduced prior to the addition of oxygen. As shown in Table I, NOHLA formation was proportional to the NOS concentration in a stoichiometry between 0.3 and 0.5 per nNOS heme. NOHLA formation took place in both aqueous and mixed organic solvent. Moreover, the production of NOHLA was not specific to the presence of dithionite as the source of the first electron. When dithionite was replaced by NADPH (see "Experimental Procedures"), the yield of NOHLA production in aqueous buffer was 0.47 ± 0.03 per heme, which is the same value as that obtained with an initial reduction by dithionite. It must be mentioned here that under similar conditions (reduction with NADPH, but with excess BH4) Abu-Soud et al. (25) did not detect the formation of NOHLA. The reason for this difference is not clear. However, we are confident in our result; the experiment was carried out under argon atmosphere, and the result was reproducible.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of BH4 on NOHLA formation after the addition of oxygen to reduced nNOS oxygenase domain, 4.5 µM, in the presence of 200 µM L-[3H]arginine. The buffer composition was that used in Fig. 1. After incubation at 15 °C for 5 min in the absence (full circles) and presence (open circles) of 20 µM BH4, the reaction was stopped by the addition of HCl (see "Experimental Procedures"). Radiolabeled L-arginine derivatives were separated by cation exchange HPLC, and fractions were analyzed by liquid scintillation counting (right scale). Left scale, background subtracted profiles; the background was the HPLC profile of L-[3H]arginine.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Formation of NOHLA as the decomposition product of oxygenated reduced nNOS or its oxygenase domain
Full-length nNOS contains BH4 in a stoichiometry of approximately one per nNOS dimer. If not otherwise stated, the buffer contained 50% ethylene glycol; for experimental conditions see "Experimental Procedures."

As shown in Table I, the oxygenase domain alone was sufficient for this reaction. The presence of BH4, however, was essential. The oxidation state of the biopterin is also important; with the oxygenase domain, no NOHLA was produced when BH4 was replaced by BH2. The low residual NOHLA production in the full-length holoenzyme in the presence of BH2 is due to endogenous BH4, which is not readily displaced by added BH2 (26).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The Oxygen Complex of Reduced nNOS in the Absence of Substrate-- By the use of subzero temperature spectroscopy, it was possible to detect an intermediate complex between reduced nNOS and molecular oxygen. This technique was employed previously to trap the analogous complex of various cytochrome P450 forms. The spectral characteristics of the complexes of both enzyme classes are quite similar, and the differences observed during complex formation (a trough at 458 nm) are due to a spectral particularity of deoxyferrous nNOS. The shoulder at 458 nm persists in reduced nNOS in the absence of the reductase domain and is not affected by BH4. The shoulder, which was noted before by others (21), may be due to the presence of a sixth ligand in a fraction of the enzyme. The additional absorbance increase at 380-390 nm suggests a hyperporphyrin spectrum, as has been reported for many ferrous complexes of cytochrome P450 (27, 28). The identity of the putative ligand cannot be established on the basis of the spectral changes, since most exogenous ligands other than O2 induce a red shift upon binding to ferrous P450 type heme.

The spectral similarity of nNOS and P450 oxygen complexes suggests that both complexes have a similar electronic configuration. Most evidence in P450 points to a structure of Fe(III)O2·, and this configuration is also expected for NOS (29). Since the same intermediate spectrum was obtained also in the absence of BH4, it may be concluded that, in substrate-free nNOS, BH4 does not perturb the electronic structure of the oxygen complex.

Stability of the Oxygen Complex-- The oxygen complex of nNOS is rather unstable, and it was necessary to lower the temperature to -30 °C to prevent its immediate autoxidation. In that aspect, nNOS resembles microsomal cytochrome P450 (18). The oxygen complex of mitochondrial P450scc is more stable (several hours at -30 °C (19)). The most stable one, the complex of soluble P450cam, can be detected without difficulty above 0 °C (at 25 °C, tau  = 90 s (14)). It appears thus that the protein environment plays a significant role in the stability of the oxygen complex. This idea is further supported by the fact that with the nNOS oxygenase domain the complex could not be detected, indicating that in this case autoxidation of the complex was much faster than its formation. Since reoxidation of the oxygenase domain was actually slower than that of the full-length enzyme, formation of the oxyferrocomplex must be considerably slower for the oxygenase domain. The origin of the effect remains to be established. One possibility might be that, in the full-length enzyme, the reductase domain enhances the oxygen association rate. Alternatively, the differences may somehow originate from the different expression systems used, since the full-length enzyme and the oxygenase domain were obtained from baculovirus-infected cells and from overexpression in E. coli, respectively.

The Oxygen Complex in the Presence of L-Arginine and BH4-- The spectral shift of the nNOS oxygen complex in the presence of L-arginine and BH4 may be interpreted in two ways. One possibility is that the substrate and BH4 interact strongly with the Fe(III)O2· complex and modify sufficiently the energy of its electronic orbitals to induce the blue shift. Examples for an effect of substrates on the Fe(III)O2· complex are found in cytochrome P450scc, which interacts with cholesterol, (22R)-hydroxycholesterol and (20R,22R)-dihydroxycholesterol. These substrates induce significant changes of the ferric spin state and thus of the P450 Soret absorbance spectrum. However, the lambda max values of the respective oxyferrous complexes range between 423 and 416 nm, while that of the complex in the absence of substrate lies at 420 nm (31), so that the substrate-induced shift never exceeds 4 nm. In contrast, the nNOS oxygen complex in the presence of substrate is blue-shifted by 12 nm.

Alternatively, the blue-shifted intermediate spectrum in nNOS may reflect a further intermediate state (reduced by a second electron) in the course of the activation of oxygen. The observation that the decomposition of this enzyme state yields NOHLA, the formation of which requires two electrons, provides strong supporting evidence in favor of this possibility. Similarly, with cytochrome P450, product formation is only possible if the oxygen complex is reduced by a second electron.

Possible configurations of such a reduced oxygen complex are shown in Fig. 6. They comprise a peroxo- (or hydroperoxo-) Fe(III) (2), an oxyferryl porphyrin pi -cation (3), or a hydroxyferryl complex (4). Forms 2 and 3 have been characterized for different cytochromes P450 and peroxidases. An oxyferrous complex reduced by one electron maintaining an intact dioxygen bond was recently reported for the D251N mutant of P450cam (32, 33), which showed a red-shifted lambda max of the Soret band (see Table II). In contrast, compound I of horseradish peroxidase (3), is characterized by a blue-shifted maximum (34). A similar blue-shifted intermediate (405 nm), reflecting form 3, was also reported for cytochrome P450scc as an intermediate compound in the reaction with (22R)-hydroperoxycholesterol, and for cytochrome P450cam as an intermediate in the reaction of the oxyferrous complex with reduced putidaredoxin (35-37). It thus appears that, relative to the oxyferrous form 1, form 2 is red-shifted, and form 3 is blue-shifted. Our interpretation of the blue-shifted NOS intermediate is therefore that it reflects form 3. Additional support for this hypothesis comes from the very recently determined crystal structure of inducible nitric-oxide synthase (38), which suggests a stabilization of form 3 by a stacking of aromatic residues with the heme. But clearly, the definite assignment of its electronic structure awaits further investigation.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 6.   Proposed mechanism of BH4-dependent reductive activation of oxyferrous NOS leading to the formation of NOHLA. The numbers correspond to the intermediates cited in the text. 1 is observed in the absence of BH4; 3 is the probable structure observed in the presence of both L-arginine and BH4. The dashed line shows the uncoupled pathway in the absence of BH4. P+ indicates porphyrin pi -cation radical.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Soret band position of oxygen complexes of selected hemoproteins

The Role of BH4 in the Reductive Activation of the Oxygen Complex-- Our results clearly show that the decomposition of the oxygen complex of nNOS in the presence of both L-arginine and BH4 results in the formation of NOHLA. This reaction requires that the Fe(III)O2·-L-arginine complex be reduced by one electron to Fe(III)O2--L-arginine, which would then decompose in several steps to Fe(III) and NOHLA. But where does the second electron, necessary to reduce Fe(III)O2·-L-arginine stem from? For several reasons, it is highly unlikely that it originates from dithionite. (i) For the related cytochrome P450 system, the second electron is exclusively provided by a specific reductase, the analogous counterpart of the reductase domain in NOS. (ii) Replacement of dithionite by NADPH did not affect the yield of NOHLA formation. (iii) Reduction of nNOS by dithionite was much slower than the formation of NOHLA. In control experiments, we measured the reduction rate between 5 and 30 °C (data not shown) and determined an activation energy of Ea = 115 kJ/mol. Extrapolation of the linear Arrhenius plot to -30 °C yielded a prohibitively slow reduction rate (tau  = 2 weeks), whereas NOHLA was formed in less than 5 min at the same temperature.

The fact that we performed our experiments in the absence of calmodulin, essential for electron transfer from the flavins to the heme (9) and that NOHLA formation was also observed with the isolated oxygenase domain rules out the flavins as the electron source. Theoretically, the two hemes within one dimer might be able to provide the electrons to account for the observed NOHLA-to-heme stoichiometry. However, since most evidence suggests that the hemes operate independently (30, 39) and that electron transfer between the hemes does not occur (40), this option is unlikely. This leaves BH4 as the prime candidate for the donor of the second electron, in perfect agreement with the observation that NOHLA formation does not take place in its absence.

The present results are therefore relevant with regard to the role of BH4 in catalysis. It has long been suspected that the redox properties of BH4 are crucial to its function, although direct evidence for its participation in the redox process is still lacking (reviewed by Mayer and Werner (41) and Hemmens and Mayer (42)). The best evidence to date in favor of a redox-active role is the observation that redox-inactive BH4 analogues can mimic the effects of BH4 on NOS dimerization, substrate affinity, and heme spin state but fail to sustain L-citrulline production (26, 43-45). However, little information is available on the question of at which stage the putative BH4 oxidation takes place and whether it occurs in the reaction with L-arginine or with NOHLA or in both steps. Concerning the latter question, it was reported that oxidized BH4-containing NOS can catalyze the conversion of substoichiometric concentrations of L-arginine into NOHLA, whereas further conversion to L-citrulline was strictly NADPH-dependent, suggesting that BH4 may serve as an electron source for the first but not for the second step (46). However, in the present experiments, no NOHLA was formed unless the enzyme was previously reduced. The cause for the divergent results is unclear. A possible explanation might be that the enzyme preparation of Campos et al. (46) contained traces of reductant, e.g. reduced flavins.

The present results demonstrate that BH4 is absolutely required for L-arginine oxidation. If our assignment of the blue-shifted intermediate as the oxyferryl complex (3) is correct, the observation that its formation is only observed in the presence of BH4 implies that BH4 is required for oxygen activation. The simplest explanation and the one favored by us is that BH4 furnishes the electron needed to reduce Fe(III)O2· (1) to Fe(III)-O-OH (2), which immediately transforms then to the Fe(IV)=O porphyrin pi -cation radical (3). Species 3 could then react with bound L-arginine via hydrogen abstraction to form species 4, the decomposition of which would liberate NOHLA and Fe(III). In the absence of BH4, the uncoupled reaction (47, 48) will occur, and compound 1 will dissociate to Fe(III) and Obardot 2 (Fig. 6). In this way, our model also explains why the redox activity of BH4 is crucial for coupling NADPH oxidation to NO formation, although it is not required for O2 reduction per se. Since only one electron is transferred in this reaction, we denote the resulting state of the biopterin formally as BH3. However, we cannot exclude the possibility that the state that is actually formed is the quinonoid-BH2 (6,7-dihydro-L-biopterin), which is the usual product in enzymatic oxidations of BH4 (41, 49) and which can be reduced to BH4 by NOS (50).

The NOHLA-to-heme ratios of <= 0.5 suggest that in nNOS as isolated, which contains approximately one equivalent of BH4 per dimer, only the BH4-containing subunit produces NOHLA. This confirms that electron transfer between the two subunits in a NOS dimer does not take place (40) and agrees with the role postulated by us for BH4 in catalysis. Similarly, in experiments with the oxygenase domain, where BH4 was added (20 µM), the NOHLA-to-heme ratio did not reach unity, although it was a little higher (0.52 instead of 0.36 under the same buffer conditions). This may be explained by an incomplete binding of BH4, which could result from a relatively high Kd of the second BH4 binding site and an increase of Kd due to the presence of ethylene glycol. The latter idea is supported by our observation that with full-length nNOS the ratio is somewhat decreased in the presence of ethylene glycol.

Conclusion-- The observations presented in this study provide important clues to the role BH4 plays in NOS catalysis. The hypothesis that electron transfer from BH4 is required for oxygen activation is the simplest explanation of our results. It does, however, need further corroboration, and it remains also to be established if the same holds true for the second step in NO catalysis, the oxidation of NOHLA to L-citrulline.

    FOOTNOTES

* This work was supported by Fonds zur Förderung der Wissenschaftlichen Forschung in Österreich Grants P 11478, P 10655, P 10859, and P 12191 and by the French-Austrian AMADEUS program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: INSERM U128, 1919 Route de Mende (CNRS), F-34293 Montpellier Cedex 5, France. Tel.: 33-4-67-61-33-65; Fax: 33-4-67-52-36-81; E-mail: lange{at}xerxes.cnrs-mop.fr.

1 The abbreviations used are: NOS, nitric-oxide synthase; NO, nitric oxide; nNOS, neuronal nitric-oxide synthase; NOHLA, Nomega -hydroxy-L-arginine; BH4, (6R)-5,6,7,8-tetrahydro-L-biopterin (tetrahydrobiopterin); BH2, 7,8-dihydro-L-biopterin; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; HPLC, high pressure liquid chromatography.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Marletta, M. A. (1994) Cell 78, 927-930[Medline] [Order article via Infotrieve]
  2. Mayer, B. (1995) in Nitric Oxide in the Nervous System (Vincent, S. R., ed), pp. 21-41, Academic Press, London
  3. Renaud, J. P., Boucher, J. L., Vadon, S., Delaforge, M., and Mansuy, D. (1993) Biochem. Biophys. Res. Commun. 192, 53-60[CrossRef][Medline] [Order article via Infotrieve]
  4. Kwon, N. S., Nathan, C. F., Gilker, C., Griffith, O. W., Matthews, D. E., and Stuehr, D. J. (1990) J. Biol. Chem. 265, 13442-13445[Abstract/Free Full Text]
  5. Leone, A. M., Palmer, R. M. J., Knowles, R. G., Francis, P. L., Ashton, D. S., and Moncada, S. (1991) J. Biol. Chem. 266, 23790-23795[Abstract/Free Full Text]
  6. Sheta, E. A., McMillan, K., and Masters, B. S. S. (1994) J. Biol. Chem. 269, 15147-15153[Abstract/Free Full Text]
  7. Tzeng, E., Billiar, T. R., Robbins, P. D., Loftus, M., and Stuehr, D. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11771-11775[Abstract]
  8. List, B. M., Klatt, P., Werner, E. R., Schmidt, K., and Mayer, B. (1996) Biochem. J. 315, 57-63[Medline] [Order article via Infotrieve]
  9. Abu-Soud, H. M., and Stuehr, D. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10769-10772[Abstract]
  10. Ortiz de Montellano, P. R. (1986) in Cytochrome P-450: Structure, Mechanism and Biochemistry (Ortiz de Montellano, P. R., ed), pp. 217-271, Plenum Press, London
  11. Eisenstein, L., Debey, P., and Douzou, P. (1977) Biochem. Biophys. Res. Commun. 77, 1377-1383[Medline] [Order article via Infotrieve]
  12. Gunsalus, I. C., Meeks, J. R., Lipscomb, J. D., Debrunner, P., and Münck, E. (1974) in Molecular Mechanisms of Oxygen Activation (Hayaishi, O., ed), pp. 561-613, Academic Press, Inc., New York
  13. Blanck, J., Smettan, G., and Greschner, S. (1984) in Cytochrome P450 (Ruckpaul, K., and Rein, H., eds), pp. 111-162, Akademie-Verlag, Berlin
  14. Bangcharoenpaurpong, O., Rizos, A. K., Champion, P. M., Jollie, D., and Sligar, S. G. (1986) J. Biol. Chem. 261, 8089-8092[Abstract/Free Full Text]
  15. Vaz, A. D. N., Pernecky, S. J., Raner, G. M., and Coon, M. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4644-4648[Abstract/Free Full Text]
  16. Abu-Soud, H. M., Gachhui, R., Raushel, F. M., and Stuehr, D. J. (1997) J. Biol. Chem. 272, 17349-17353[Abstract/Free Full Text]
  17. Douzou, P. (1977) Cryobiochemistry, pp. 45-90, Academic Press, London
  18. Bonfils, C., Debey, P., and Maurel, P. (1979) Biochem. Biophys. Res. Commun. 88, 1301-1307[Medline] [Order article via Infotrieve]
  19. Larroque, C., and van Lier, J. E. (1980) FEBS Lett. 115, 175-176[CrossRef][Medline] [Order article via Infotrieve]
  20. Harteneck, C., Klatt, P., Schmidt, K., and Mayer, B. (1994) Biochem. J. 304, 683-686[Medline] [Order article via Infotrieve]
  21. Sono, M., Stuehr, D. J., Ikeda-Saito, M., and Dawson, J. H. (1995) J. Biol. Chem. 270, 19943-19948[Abstract/Free Full Text]
  22. Coon, M. J., van der Haeven, T. A., Dahl, S. B., and Haugen, D. A. (1978) Methods Enzymol. 52, 109-117[Medline] [Order article via Infotrieve]
  23. Mayer, B., Klatt, P., Werner, E. R., and Schmidt, K. (1994) Neuropharmacology 33, 1253-1259[CrossRef][Medline] [Order article via Infotrieve]
  24. Klatt, P., Schmidt, K., Uray, G., and Mayer, B. (1993) J. Biol. Chem. 268, 14781-14787[Abstract/Free Full Text]
  25. Abu-Soud, H. M., Presta, A., Mayer, B., and Stuehr, D. J. (1997) Biochemistry 36, 10811-10816[CrossRef][Medline] [Order article via Infotrieve]
  26. Klatt, P., Schmid, M., Leopold, E., Schmidt, K., Werner, E. R., and Mayer, B. (1994) J. Biol. Chem. 269, 13861-13866[Abstract/Free Full Text]
  27. Dawson, J. H., Andersson, L. A., and Sono, M. (1983) J. Biol. Chem. 258, 13637-13645[Abstract/Free Full Text]
  28. Dawson, J. D., and Sono, M. (1987) Chem. Rev. 87, 1255-1276
  29. Korth, H. G., Sustmann, R., Thater, C., Butler, A. R., and Ingold, K. U. (1994) J. Biol. Chem. 269, 17776-17779[Abstract/Free Full Text]
  30. Gorren, A. C. F., List, B. M., Schrammel, A., Pitters, E., Hemmens, B., Werner, E. R., Schmidt, K., and Mayer, B. (1996) Biochemistry 35, 16735-16745[CrossRef][Medline] [Order article via Infotrieve]
  31. Tuckey, R. C., and Kamin, H. (1982) J. Biol. Chem. 257, 9309-9314[Abstract/Free Full Text]
  32. Gerber, N. C., and Sligar, S. G. (1994) J. Biol. Chem. 269, 4260-4266[Abstract/Free Full Text]
  33. Benson, D. E., Suslick, K. S., and Sligar, S. G. (1997) Biochemistry 36, 5104-5107[CrossRef][Medline] [Order article via Infotrieve]
  34. DiNello, R. K., and Dolphin, D. H. (1981) J. Biol. Chem. 256, 6903-6912[Abstract/Free Full Text]
  35. Lange, R., Larroque, C., and van Lier, J. E. (1988) Biochem. Life Sci. Adv. 7, 137-140
  36. Lange, R., Hui Bon Hoa, G., Larroque, C., and Gunsalus, I. C. (1989) in Cytochrome P-450: Biochemistry and Biophysics (Schuster, I., ed), pp. 272-275, Taylor & Francis, London
  37. Larroque, C., Lange, R., Maurin, L., Bienvenüe, A., and van Lier, J. E. (1990) Arch. Biochem. Biophys. 282, 198-201[Medline] [Order article via Infotrieve]
  38. Crane, B. R., Arvai, A. S., Gachhui, R., Wu, C., Gosh, D. K., Getzoff, E. D., Stuehr, D. J., and Tainer, J. A. (1997) Science 278, 425-431[Abstract/Free Full Text]
  39. Gorren, A. C. F., Schrammel, A., Schmidt, K., and Mayer, B. (1997) Biochemistry 36, 4360-4366[CrossRef][Medline] [Order article via Infotrieve]
  40. Siddhanta, U., Wu, C., Abu-Soud, H. M., Zhang, J., Ghosh, D. K., and Stuehr, D. J. (1996) J. Biol. Chem. 271, 7309-7312[Abstract/Free Full Text]
  41. Mayer, B., and Werner, E. R. (1995) Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 453-463[Medline] [Order article via Infotrieve]
  42. Hemmens, B., and Mayer, B. (1997) Methods Mol. Biol. 100, 1-32
  43. Werner, E. R., Pitters, E., Schmidt, K., Wachter, H., Werner-Felmayer, G., and Mayer, B. (1996) Biochem. J. 320, 193-196[Medline] [Order article via Infotrieve]
  44. Mayer, B., Wu, C., Gorren, A. C. F., Pfeiffer, S., Schmidt, K., Clark, P., Stuehr, D. J., and Werner, E. R. (1997) Biochemistry 36, 8422-8427[CrossRef][Medline] [Order article via Infotrieve]
  45. Pfeiffer, S., Gorren, A. C. F., Pitters, E., Schmidt, K., Werner, E. R., and Mayer, B. (1997) Biochem. J. 328, 349-352[Medline] [Order article via Infotrieve]
  46. Campos, K. L., Giovanelli, J., and Kaufman, S. (1995) J. Biol. Chem. 270, 1721-1728[Abstract/Free Full Text]
  47. Heinzel, B., John, M., Klatt, P., Böhme, E., and Mayer, B. (1992) Biochem. J. 281, 627-630[Medline] [Order article via Infotrieve]
  48. Pou, S., Pou, W. S., Bredt, D. S., Snyder, S. H., and Rosen, G. M. (1992) J. Biol. Chem. 267, 24173-24176[Abstract/Free Full Text]
  49. Kaufman, S. (1993) Annu. Rev. Nutr. 13, 261-286[CrossRef][Medline] [Order article via Infotrieve]
  50. Witteveen, C. F. B., Giovanelli, J., and Kaufman, S. (1996) J. Biol. Chem. 271, 4143-4147[Abstract/Free Full Text]
  51. Blumberg, W. E., Peisach, J., Wittenberg, B. A., and Wittenberg, J. B. (1968) J. Biol. Chem. 243, 1854-1862[Abstract/Free Full Text]
  52. Palcic, M. M., Rutter, R., Araiso, T., Hager, L. P., and Dunford, B. (1980) Biochem. Biophys. Res. Commun. 94, 1123-1127[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.